Literature DB >> 10897216

[Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].

K Kuwata1, S Nagayama, Y Hirakawa, E Matsushima, Y Kawaguchi.   

Abstract

Toxic effects (neurotoxicity and cardiotoxicity) of 5-FU and its derivatives have been reported by many investigators. These toxicities are considered to be caused by the inhibition of the TCA cycle by alpha-fluoro-beta-alanine (FBAL), a metabolite of 5-FU, and later metabolites. In this study, we focused on FBAL as an index of the above toxicities. We compared the concentrations of 5-FU and FBAL in plasma after administration of UFT, tegafur (FT), 5-FU or doxifluridine (5'-DFUR) to rats (75 mumol/kg) in order to evaluate which compound has the better balance of efficacy and toxicity. UFT exhibited the lowest FBAL concentration in plasma followed by FT, 5'-DFUR and 5-FU. The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds. These data indicate that the lowest ratio of FBAL to 5-FU resulted from the inhibitory effect of uracil, a component of UFT, on the metabolism of 5-FU. In conclusion, the present results suggest that UFT has a better balance of efficacy and toxicity than FT, 5-FU and 5'-DFUR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897216

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.

Authors:  Katsuki Muneoka; Yoshio Shirai; Naoyuki Yokoyama; Toshifumi Wakai; Katsuyoshi Hatakeyama
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

2.  Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.

Authors:  Y Yamada; T Hamaguchi; M Goto; K Muro; Y Matsumura; Y Shimada; K Shirao; S Nagayama
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.